<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Oral <z:chebi fb="0" ids="3207">budesonide</z:chebi> in adult studies is a potent <z:chebi fb="0" ids="50858">corticosteroid</z:chebi> with decreased systemic bioavailability and an improved adverse effect profile in comparison with <z:chebi fb="0" ids="8382">prednisone</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>It has recently been introduced for the treatment of <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> in Europe, Canada, and Israel </plain></SENT>
<SENT sid="2" pm="."><plain>Benign intracranial <z:hpo ids='HP_0000822'>hypertension</z:hpo> has rarely been associated with <z:chebi fb="0" ids="50858">corticosteroid</z:chebi> therapy but has not been reported in association with <z:chebi fb="0" ids="3207">budesonide</z:chebi> therapy </plain></SENT>
<SENT sid="3" pm="."><plain>Three adolescents with <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> and poor nutritional status developed benign intracranial <z:hpo ids='HP_0000822'>hypertension</z:hpo> while receiving oral <z:chebi fb="0" ids="3207">budesonide</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> three patients had previously received multiple courses of <z:chebi fb="0" ids="8382">prednisone</z:chebi> during the course of their disease, without developing intracranial <z:hpo ids='HP_0000822'>hypertension</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Benign intracranial <z:hpo ids='HP_0000822'>hypertension</z:hpo> resolved after medication withdrawal and did not recur with subsequent use of <z:chebi fb="0" ids="8382">prednisone</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>Evaluation for benign intracranial <z:hpo ids='HP_0000822'>hypertension</z:hpo> should be considered in patients with <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> who develop <z:hpo ids='HP_0002315'>headache</z:hpo> while receiving oral <z:chebi fb="0" ids="3207">budesonide</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>This side effect may be associated with poor nutritional status </plain></SENT>
</text></document>